MAP Kinase Kinase Kinases

• 

  Subject Areas on Research

  • A MAP kinase cascade composed of cell type specific and non-specific elements controls mating and differentiation of the fungal pathogen Cryptococcus neoformans. 
  • A Small Molecule Pyrazolo[3,4-d]Pyrimidinone Inhibitor of Zipper-Interacting Protein Kinase Suppresses Calcium Sensitization of Vascular Smooth Muscle. 
  • A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma. 
  • A new identity for MLK3 as an NIMA-related, cell cycle-regulated kinase that is localized near centrosomes and influences microtubule organization. 
  • A ubiquitin E2 variant protein acts in axon termination and synaptogenesis in Caenorhabditis elegans. 
  • Alternative activation of extracellular signal-regulated protein kinases in curcumin and arsenite-induced HSP70 gene expression in human colorectal carcinoma cells. 
  • Autism spectrum disorder susceptibility gene TAOK2 affects basal dendrite formation in the neocortex. 
  • Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. 
  • Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status. 
  • COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. 
  • Cell-cycle control of cell polarity in yeast. 
  • Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer. 
  • Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types. 
  • Disruption of Mekk2 in mice reveals an unexpected role for MEKK2 in modulating T-cell receptor signal transduction. 
  • Dynamic microtubules drive circuit rewiring in the absence of neurite remodeling. 
  • ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma. 
  • Feedback inhibition of G protein-coupled receptor kinase 2 (GRK2) activity by extracellular signal-regulated kinases. 
  • Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. 
  • Genetic and pharmacological validation of TAK1 inhibition in macrophages as a therapeutic strategy to effectively inhibit TNF secretion. 
  • Genetic modifiers of the severity of sickle cell anemia identified through a genome-wide association study. 
  • Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells. 
  • Identification of the MATa mating-type locus of Cryptococcus neoformans reveals a serotype A MATa strain thought to have been extinct. 
  • Inhibition of Cdc42 during mitotic exit is required for cytokinesis. 
  • Inhibition of the cardiomyocyte-specific troponin I-interacting kinase limits oxidative stress, injury, and adverse remodeling due to ischemic heart disease. 
  • Insulin activates a novel adipocyte mitogen-activated protein kinase kinase kinase that shows rapid phasic kinetics and is distinct from c-Raf. 
  • Ligation of prostate cancer cell surface GRP78 activates a proproliferative and antiapoptotic feedback loop: a role for secreted prostate-specific antigen. 
  • Loss of MST/Hippo Signaling in a Genetically Engineered Mouse Model of Fusion-Positive Rhabdomyosarcoma Accelerates Tumorigenesis. 
  • MEK inhibition in the treatment of advanced melanoma. 
  • Mechanisms of proinflammatory cytokine-induced biphasic NF-kappaB activation. 
  • Mekk3 is essential for early embryonic cardiovascular development. 
  • Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients. 
  • Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. 
  • Novel genetic variants in the P38MAPK pathway gene ZAK and susceptibility to lung cancer. 
  • Overexpression of TNNI3K, a cardiac-specific MAPKKK, promotes cardiac dysfunction. 
  • PAK kinases Ste20 and Pak1 govern cell polarity at different stages of mating in Cryptococcus neoformans. 
  • PAKa, a putative PAK family member, is required for cytokinesis and the regulation of the cytoskeleton in Dictyostelium discoideum cells during chemotaxis. 
  • Pharmacological inhibition of TAK1, with the selective inhibitor takinib, alleviates clinical manifestation of arthritis in CIA mice. 
  • Potentiation of signal transduction mitogenesis and cellular proliferation upon binding of receptor-recognized forms of alpha2-macroglobulin to 1-LN prostate cancer cells. 
  • Preclinical efficacy of MEK inhibition in Nras-mutant AML. 
  • Regulation of DLK-1 kinase activity by calcium-mediated dissociation from an inhibitory isoform. 
  • Regulation of zipper-interacting protein kinase activity in vitro and in vivo by multisite phosphorylation. 
  • Role of Cdc42p in pheromone-stimulated signal transduction in Saccharomyces cerevisiae. 
  • Ssk2 mitogen-activated protein kinase kinase kinase governs divergent patterns of the stress-activated Hog1 signaling pathway in Cryptococcus neoformans. 
  • T cell activation up-regulates the expression of the focal adhesion kinase Pyk2: opposing roles for the activation of protein kinase C and the increase in intracellular Ca2+. 
  • TAK1 regulates SOX9 expression in chondrocytes and is essential for postnatal development of the growth plate and articular cartilages. 
  • TAK1 regulates cartilage and joint development via the MAPK and BMP signaling pathways. 
  • Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease. 
  • Temporomandibular joint pain: a critical role for Trpv4 in the trigeminal ganglion. 
  • The DLK-1 kinase promotes mRNA stability and local translation in C. elegans synapses and axon regeneration. 
  • The MEK pathway is required for stimulation of p21(WAF1/CIP1) by transforming growth factor-beta. 
  • The broad spectrum mixed-lineage kinase 3 inhibitor URMC-099 prevents acute microgliosis and cognitive decline in a mouse model of perioperative neurocognitive disorders. 
  • The combination of TPL2 knockdown and TNFα causes synthetic lethality via caspase-8 activation in human carcinoma cell lines.